One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Delcath Systems logo
Delcath Systems DCTH
$ 14.7 -0.41%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Delcath Systems Income Statement 2025-1988 | DCTH

Brief overview of financial performance at Delcath Systems

This overview is based on financial performance over the past five years. Revenue at Delcath Systems moved from $1.2 million in 2020 to $85.2 million in 2025. The total change was +7272.9%, with a CAGR of approximately 136.3%. Revenue growth reflects a pronounced phase of business expansion.

The gross result shifted from 1 million dollars to 73.4 million dollars, or +7199.6%. Cost of revenue developed more favorably than sales, supporting gross profitability. Gross profit as a share of revenue changed from 87% to 86.2%. There was no meaningful shift in gross profitability.

Over the period, EBITDA shifted from −24 million dollars to 898 thousand dollars, a change of +103.7%. EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from −2075.2% to 1.1%. A wider margin confirms stronger operating efficiency.

Comparing the endpoints shows a move from −24.2 million dollars to 2.7 million dollars. A negative result turned positive over the five years.

Market capitalization changed from $69.3 million to $326 million (+371.2%). Valuation expanded much faster than the underlying results.

Conclusion

The results present an uneven picture without one dominant signal. Key strengths include an improving EBITDA margin, revenue expansion and a stronger final result. The most visible risks are a narrow EBITDA buffer. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Delcath Systems

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 1988

Market Cap

326 M 375 M 74.8 M 51.3 M 49.3 M 69.3 M 337 K 7.48 M 5.07 K 21.4 M - - 5.68 B - - - - - -

Shares

35.8 M 28.5 M 16.2 M 8.86 M 7.15 M 4.29 M 25.9 K 38.2 K 325 325 - - 325 - - 39 M - - -

Historical Prices

9.11 13.2 4.61 5.79 6.9 16.1 13 198 - - - - - - - - - - -

Net Income

2.7 M -26.4 M -47.7 M -36.5 M -25.6 M -24.2 M -8.88 M -19.2 M -45.1 M -18 M -14.7 M -17.4 M -30.3 M -51.9 M -30.9 M -46.7 M -22.1 M - -

Revenue

85.2 M 37.2 M 2.06 M 2.72 M 3.56 M 1.16 M 1.58 M 3.41 M 2.72 M 1.99 M 1.75 M 1.07 M 790 K 346 K - - - - -

Cost of Revenue

11.8 M 6.19 M 635 K 686 K 671 K 640 K 719 K 1.01 M 701 K 550 K 462 K 291 K 464 K 39 K - - - - -

Gross Profit

73.4 M 31 M 1.43 M 2.03 M 2.88 M 1.01 M 861 K 2.4 M 2.01 M 1.44 M 1.28 M 778 K 326 K 307 K - - - - -

Operating Income

660 K -12.4 M -38.2 M -33.9 M -24.5 M -21.3 M -19.9 M -27.1 M -18.2 M -16.4 M -15.2 M -19.3 M -33 M -53.9 M -46.5 M -30.7 M -13.5 M - -

Interest Expense

-70 K -30 K -59 K 30 K 68 K 154 K 2 K 51 K 21.7 M 14.3 M 67 K -24 K -81 K - - - - - -

EBITDA

898 K -12.3 M -38.1 M -33.7 M -24.4 M -24 M -18.1 M -26.6 M -17.9 M -16.1 M -14.6 M -18.3 M -31.9 M -52.5 M -45.4 M -30.3 M -13.5 M - -

Operating Expenses

72.8 M 43.4 M 39.6 M 35.9 M 27.4 M 22.3 M 20.8 M 29.5 M 20.2 M 17.9 M 16.5 M 20.1 M 33.3 M 54.2 M 46.5 M - - - -

General and Administrative Expenses

43.5 M 29.6 M 22.1 M 17.3 M 13.6 M 11.1 M 11.3 M 9.82 M 9.68 M 9.43 M 10 M 15.8 M 20.7 M 28 M 21.3 M 13.2 M 3.9 M - -

All numbers in USD currency

Quarterly Income Statement Delcath Systems

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

35.9 M 36 M 36.4 M 35.8 M 34.6 M 33.1 M 28.7 M 28.4 M 24.9 M 22.8 M 17.9 M 12.5 M 11.6 M 10 M 9.22 M 8.19 M 8.19 M 7.91 M 7.59 M 6.68 M 6.5 M 6 M 4.29 M 2.27 M 72.7 K 67.1 K 102 K 102 K 105 K 14.7 K 35.9 M 917 K 659 K 228 K 2.76 K 1.42 K 248 11.8 K 4.35 K 1.51 M 1.46 M 1.36 M 1.23 M 12.2 M 10.9 M 9.71 M 9.45 M 9.43 M 9.3 M 8.4 M 6.25 M 6.02 M 5.34 M 76.8 M 67.2 M 54.8 M 48.3 M 48.2 M 47 M 43 M 48.2 M

Net Income

2.67 M -1.07 M 830 K 2.7 M 1.07 M - 1.86 M -13.7 M -11.1 M - -20.3 M -7.2 M -9 M - -8.88 M -10.2 M -9 M - -7.12 M -6.43 M -6.75 M - -4.99 M -4.28 M -7.86 M - -7.52 M -5.96 M -7.89 M - -8.88 M -6.66 M 7.18 M -19.2 M -12.6 M -1.94 M -11.3 M -8.49 M -1 M -6.67 M -1.81 M -5.1 M -2.42 M -3.7 M -3.49 M -2.94 M -4.56 M -4.6 M -5.28 M -4.79 M -7.21 M -5.48 M -12.8 M -10.7 M -11.8 M -14.5 M -14.9 M -15.3 M -8.31 M -5.46 M -1.85 M

Revenue

29.1 M 25 M 20.6 M 24.2 M 19.8 M - 11.2 M 7.77 M 3.14 M - 434 K 495 K 597 K - 906 K 797 K 378 K - - - - - - - - - - - - - 824 K 858 K - - 684 K 584 K - - - - - - - - - - 217 K 251 K 310 K - 72 K - 381 K - 39 K 106 K - - - - -

Cost of Revenue

2.98 M 3.74 M 2.62 M 3.32 M 2.84 M - 1.64 M 1.52 M 903 K - 133 K 150 K 181 K - 235 K 180 K 33 K - 227 K 202 K 112 K - 188 K 168 K 78 K - 172 K 172 K 96 K - 233 K 220 K 147 K - 172 K 135 K 219 K - 112 K 150 K 111 K - 90 K 137 K 133 K - 50 K 66 K 93 K - 23 K 332 K 31 K - - - - - - - -

Gross Profit

26.1 M 21.3 M 17.9 M 20.8 M 16.9 M - 9.56 M 6.25 M 2.24 M - 301 K 345 K 416 K - 671 K 617 K 345 K - 295 K 334 K 276 K - 278 K 211 K 216 K - 208 K 240 K 174 K - 591 K 638 K 555 K - 512 K 449 K 524 K - 323 K 361 K 259 K - 309 K 329 K 311 K - 167 K 185 K 217 K - 49 K -332 K 350 K - 39 K 106 K - - - - -

Operating Income

2.4 M -1.64 M -388 K 2.59 M 642 K - -1.26 M -3.91 M -10.3 M - -10.6 M -8 M -8.32 M - -8.17 M -9.49 M -8.34 M - -6.7 M -6.45 M -6.73 M - -4.98 M -4.27 M -5.07 M - -5.57 M -4.13 M -5.67 M - -5.79 M -6.09 M -7.5 M -4.72 M -4.63 M -4.6 M -4.21 M -4.38 M -4.72 M -3.87 M -3.46 M -4.23 M -3.65 M -3.62 M -3.71 M -3.28 M -5.05 M -5.9 M -5.06 M -5.53 M -6.7 M -10.6 M -10.2 M -11.8 M -12.2 M -15.3 M -14.6 M 16 M 12.2 M 10.5 M 7.81 M

Interest Expense

-17 K -58 K -33 K -34 K 4 K - 35 K 10 K -22 K - -5 K 6 K 13 K - 26 K -8 K -15 K - -9 K 61 K 21 K - 33 K - - - 4 K 1 K 2 K - -10 K -5 K -5 K - 5.04 M 6.92 M 8 K - 4.96 M 1.61 M -28 K - -11 K -28 K 11 K - -23 K 7 K -15 K - - - - - - - - - - - -

EBITDA

2.5 M -1.54 M -288 K 2.69 M 685 K - -1.16 M -3.81 M -10.2 M - -10.5 M -7.9 M -8.3 M - -8.07 M -9.39 M -8.31 M - -6.58 M -6.37 M -6.69 M - -4.86 M -4.18 M -5.03 M - -5.47 M -4.03 M -5.61 M - -5.69 M -5.99 M -7.38 M -4.72 M -4.53 M -4.5 M -4.14 M -4.38 M -4.62 M -3.77 M -3.38 M -4.23 M -3.55 M -3.42 M -3.51 M -3.28 M -4.85 M -5.6 M -4.81 M -5.53 M -6.4 M -10.3 M -9.9 M -11.8 M -11.9 M -14.9 M -14.2 M 16 M 12.9 M 10.9 M 8.03 M

Operating Expenses

23.8 M 22.9 M 18.3 M 18.2 M 16.3 M - 10.8 M 10.2 M 12.5 M - 10.9 M 8.34 M 8.74 M - 8.84 M 10.1 M 8.68 M - 6.99 M 6.78 M 7 M - 5.26 M 4.48 M 5.29 M - 5.78 M 4.37 M 5.85 M - 6.38 M 6.73 M 8.06 M 5.25 M 5.14 M 5.05 M 4.74 M 4.88 M 5.05 M 4.23 M 3.72 M - 3.96 M 3.95 M 4.02 M - 5.22 M 6.09 M 5.28 M - - - - - - - - - - - -

General and Administrative Expenses

13.4 M 13.1 M 10.3 M 11.4 M 11.3 M - 6.95 M 6.76 M 8.81 M - 6.2 M 4.79 M 4.16 M - 4.78 M 4.5 M 4.2 M - 4.04 M 3.29 M 3.3 M - 2 M 2.26 M 2.32 M - 4 M 2.65 M 2.55 M - 2.28 M 2.64 M 2.37 M - 2.86 M 2.53 M 2.42 M - 2.36 M 2.29 M 2.38 M - 2.28 M 2.5 M 3.04 M - 4.54 M 4.6 M 3.82 M - 4.57 M 6.26 M 6.08 M - 6.96 M 7.22 M 7.42 M - 5.74 M 5.24 M 4.17 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Delcath Systems (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Outset Medical Outset Medical
OM
$ 4.05 -4.03 % $ 61.6 K usaUSA
PAVmed PAVmed
PAVM
$ 2.1 -6.05 % $ 1.41 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.69 -3.89 % $ 172 M canadaCanada
CONMED Corporation CONMED Corporation
CNMD
$ 47.11 -0.99 % $ 1.46 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 2.79 2.57 % $ 119 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 15.29 10.8 % $ 426 M australiaAustralia
Sintx Technologies Sintx Technologies
SINT
$ 1.73 0.58 % $ 4.8 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 29.23 -0.32 % $ 25.3 B britainBritain
TELA Bio TELA Bio
TELA
$ 1.08 -0.92 % $ 50.7 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 16.35 -1.03 % $ 1.11 B usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 71.07 -0.38 % $ 2.09 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.77 1.68 % $ 13 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 87.81 -0.49 % $ 1.12 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.75 -0.51 % $ 379 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.42 0.11 % $ 763 M usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.13 -4.2 % $ 1.34 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 6.1 -0.41 % $ 824 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 11.84 -11.18 % $ 908 M usaUSA
Inogen Inogen
INGN
$ 6.67 -0.3 % $ 177 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.03 -0.78 % $ 907 M israelIsrael
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 93.03 -1.71 % $ 119 B usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 88.4 0.12 % $ 51.7 B usaUSA
Myomo Myomo
MYO
$ 1.26 0.39 % $ 52.7 M usaUSA
Beyond Air Beyond Air
XAIR
$ 2.34 6.85 % $ 19.4 B usaUSA
Globus Medical Globus Medical
GMED
$ 78.68 -0.35 % $ 10.6 B usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 141.9 -0.52 % $ 9.98 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.3 -2.31 % $ 41.9 M usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 2.86 4.0 % $ 46.7 M usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 23.28 -1.02 % $ 532 M usaUSA
Penumbra Penumbra
PEN
$ 323.56 -0.25 % $ 12.6 B usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 297.6 -2.23 % $ 114 B usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 94.86 -1.19 % $ 18.8 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.33 5.9 % $ 680 M israelIsrael
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.38 -6.87 % $ 24.6 M israelIsrael
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 23.84 1.45 % $ 559 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 3.74 -11.58 % $ 553 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA